Speciality European Pharma Limited
Quick facts
Phase 3 pipeline
- Goserelin plus Bicalutamide · Oncology
Goserelin suppresses testosterone production via GnRH receptor agonism, while bicalutamide blocks androgen receptor signaling, providing dual hormonal suppression for androgen-dependent cancers.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Speciality European Pharma Limited portfolio CI brief
- Speciality European Pharma Limited pipeline updates RSS
Frequently asked questions about Speciality European Pharma Limited
What is Speciality European Pharma Limited's pipeline?
Speciality European Pharma Limited has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Goserelin plus Bicalutamide.
Related
- Sector hub: All tracked pharma companies